FDA seeks comments on ibogaine research safeguards through November 20
FDA invites comments through November 20 on proposed safeguards for early-stage ibogaine clinical research.
What the record says
FDA’s October 5 announcement seeks input on early-phase ibogaine study design, monitoring, participant eligibility and oversight.
The October 6 Federal Register notice identifies docket FDA-2026-N-10429. Electronic comments close at 11:59 p.m. Eastern on November 20, 2026; paper comments must arrive by November 20.
FDA describes preliminary research considerations, not final regulatory requirements or approval of an ibogaine treatment.
Source details and supporting locations.
Practical next step
Search FDA-2026-N-10429 on Regulations.gov and follow the docket instructions. Electronic comments and attachments are publicly posted; use the Federal Register notice’s separate paper process for confidential information.
Limits and what is not established
This consultation does not offer trial enrollment or establish treatment approval, safety or effectiveness. FDA identifies serious safety concerns. No dosing or treatment advice is provided.
Sources checked October 10, 2026. Later notices may change instructions or arrangements.
Original sources
U.S. Food and Drug Administration: original information
Federal Register, U.S. Government Publishing Office: original information